FDA 483 - Apitoria Pharma Private Limited - August 12, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Aurobindo Pharma Limited (Unit I), an Active Pharmaceutical Ingredient Manufacturer in Doulatabad, India, revealed significant quality system deficiencies. The firm failed to adequately qualify suppliers, implement scientifically sound sampling plans, and ensure components were tested prior to use. Additionally, issues were noted with the evaluation of manufacturing changes, the scientific soundness of investigations into discrepancies, equipment maintenance, and the timely documentation of quality-related activities.
ID · 29b3d942-d6ae-4757-ac08-abd02cdeacc1